The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis

Abstract

Purpose. This study is aimed at systematically analyzing the expression, function, and prognostic value of six transmembrane epithelial antigen of the prostate 1 (STEAP1) in various cancers. Methods. The expressions of STEAP1 between normal and tumor tissues were analyzed using TCGA and GTEx. Clinicopathologic data was collected from GEPIA and TCGA. Prognostic analysis was conducted by Cox proportional hazard regression and Kaplan-Meier survival. DNA methylation, mutation features, and molecular subtypes of cancers were also investigated. The top-100 coexpressed genes with STEAP1 were involved in functional enrichment analysis. ESTIMATE algorithm was used to analyze the correlation between STEAP1 and immunity value. The relationships of STEAP1 and biomarkers including tumor mutational burden (TMB), microsatellite instability (MSI), and stemness score as well as chemosensitivity were also illustrated. Results. Among 33 cancers, STEAP1 was overexpressed in 19 cancers such as cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon adenocarcinoma, and lymphoid neoplasm diffuse large B cell lymphoma while was downregulated in 5 cancers such as adrenocortical carcinoma, breast invasive carcinoma (BRCA), and kidney chromophobe renal cell carcinoma. STEAP1 has significant prognostic relationships in multiple cancers. 15 cancers exhibited differences of DNA methylation including bladder urothelial carcinoma, BRCA, and CESC. STEAP1 expression was positively correlated to immune molecules especially in thyroid carcinoma and negatively especially in uveal melanoma. STEAP1 was associated with TMB and MSI in certain cancers. In addition, STEAP1 was connected with increased chemosensitivity of drugs such as trametinib and pimasertib. Conclusions. STEAP1 was an underlying target for prognostic prediction in different cancer types and a potential biomarker of TMB, MSI, tumor microenvironment, and chemosensitivity.

Pan-Cancer Analysis of the Prognostic and Immunological Role of <i>SMG5</i>: A Biomarker for Cancers

“…Researchers have found that ICP genes play a crucial role in the regulation of immune cell infiltration and cancer therapy [23]. We further analyzed the relationship between SMG5 expression and ICP genes and found that all tumors had a part of ICP genes associated with SMG5 expression, and 29 out of 47 ICP genes in LGG were associated with SMG5 expression (Fig.…”

“…SMG5 mRNA expression levels and cell sensitivity data z-scores (GI50) in 60 different cancer cell lines were retrieved by accessing the NCI-60 database using the CellMiner interface (https://discover.nci.nih.gov/cellminer/) [23], and Pearson’s correlation analysis was used to analyze the correlation between SMG5 expression levels and drug scores.…”

EFEMP1 binds to STEAP1 to promote osteosarcoma proliferation and invasion via the Wnt/β-catenin and TGF-β/Smad2/3 signal pathways

“…As a promising candidate target, STEAP1 has been a recent focus of a number of studies targeting prostate cancer, such as antibody-drug conjugation therapy [15] , T cell immunotherapy [16] , fusion protein vaccines [17] , and the early detection of metastatic prostate cancer [11] . The expression pattern of STEAP1 varies among tumor types, and the role of STEAP1 in different aspects of malignant tumor phenotypes is controversial [5] , [18] . High STEAP1 expression in Ewing's sarcoma is a marker of tumor invasiveness and could induce an resultful T cell mediated anti-cancer reaction [19] , [20] .…”

The Prognostic Value of lncRNA MCM3AP-AS1 on Clinical Outcomes in Various Cancers: A Meta- and Bioinformatics Analysis

“…To improve the prognosis of patients with cancer, an increasing number of studies have identified biomarkers that can predict cancer prognosis through bioinformatics analysis, such as Zhao et al who found that aberrant expression of STEAP1 in pancancer predicted survival and CFS and could be a potential therapeutic target [50]. Chen et al suggested that ALKBH7 may serve as a potential prognostic pancancer biomarker and is involved in the immune response [51].…”